Global edition
Region
NewsWebcastsPodcastsThe Magazine
Sign inSubscribe
Follow Pharma Now@pharmanow.live
Editions & local coverage
United StatesUnited KingdomGermanyFranceItalyIndiaSwitzerlandSingapore

A global knowledge and leadership platform for pharma. We turn complexity into clarity professionals can act on.

Get the Pharma Now app

Read offline, save stories and never miss an edition.

Get it onGoogle PlayDownload on theApp Store
Verticals
  • Microbiology & CCS
  • Pharma IT
  • Pharma Marketing
  • Regulatory Intelligence
  • Bio Pharma
  • Future Pharma Trends
Formats
  • News & Analysis
  • Interviews
  • Webcasts
  • Podcasts
  • Events
  • Magazine
Knowledge Hub
  • Knowledge Hub
  • Research Papers
  • Buyer’s Guides
  • Companies
  • Newsletter Archive
  • Glossary
Company
  • Advisory Board
  • Contributors
  • Write for Us
  • Submit a PR
  • Contact
  • Advertise
Account
  • Subscribe
  • Sign in
  • My Account
Frequently asked

Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews with industry experts.

Pharma Now provides comprehensive coverage, including: - Industry news and updates - Interviews with global pharma leaders - Market insights and trends - Innovations in AI, manufacturing, and pharma operations - Case studies, thought leadership articles, and regulatory updates

Pharma Now caters to a wide range of professionals within the pharmaceutical industry, including C-level executives, R&D professionals, quality managers, regulatory affairs specialists, and business leaders looking to stay informed about global trends and innovations.

You can subscribe to Pharma Now by visiting the Pharma Now website and choosing between print and digital editions.

Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights.

Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage, advertisers can reach a targeted audience of pharma professionals. For details, visit the Advertise With Us section on the website.

Copyright © 2026 Tantragyan Technologies Pvt Ltd. All Rights Reserved.
Privacy PolicyTerms of UseContact UsAdvertise
Breaking
NewsWHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC OutbreakNewsWHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and RemdesivirNewsAarti Pharmalabs Inaugurates Tarapur Block, Lifting Xanthine Derivatives Capacity to 9,600 TPAAI in pharmaRockwell Automation and Cisco Sign Manufacturing Partnership to Advance AI-Driven Operations in IndiaNewsRoche Establishes Second India Digital Tech Hub in Hyderabad for Global OperationsNewsSanofi Gains FDA Annual Approval for Fluzone and Fluzone High-Dose for 2026–27 Season
NewsWHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC OutbreakNewsWHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and RemdesivirNewsAarti Pharmalabs Inaugurates Tarapur Block, Lifting Xanthine Derivatives Capacity to 9,600 TPAAI in pharmaRockwell Automation and Cisco Sign Manufacturing Partnership to Advance AI-Driven Operations in IndiaNewsRoche Establishes Second India Digital Tech Hub in Hyderabad for Global OperationsNewsSanofi Gains FDA Annual Approval for Fluzone and Fluzone High-Dose for 2026–27 Season
Pharma News

The day in pharma, read in minutes.

Updated Jul 03, 2026
WHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC Outbreak
News

WHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC Outbreak

WHO lists first molecular diagnostic for Ebola Bundibugyo virus under EUL, seven weeks after PHEIC declaration over the DRC outbreak.

Vaibhavi M.Jul 03, 20262 min read
Also developing
News

WHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and Remdesivir

Vaibhavi M. · Jul 03, 2026
WHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and Remdesivir
News

Aarti Pharmalabs Inaugurates Tarapur Block, Lifting Xanthine Derivatives Capacity to 9,600 TPA

Pharma Now Editorial Team · Jul 03, 2026
Aarti Pharmalabs Inaugurates Tarapur Block, Lifting Xanthine Derivatives Capacity to 9,600 TPA
AI in pharma

Rockwell Automation and Cisco Sign Manufacturing Partnership to Advance AI-Driven Operations in India

Vaibhavi M. · Jul 03, 2026
Rockwell Automation and Cisco Sign Manufacturing Partnership to Advance AI-Driven Operations in India
News

Roche Establishes Second India Digital Tech Hub in Hyderabad for Global Operations

Pharma Now Editorial Team · Jul 03, 2026
Roche Establishes Second India Digital Tech Hub in Hyderabad for Global Operations

Latest news

11 stories
NewsNew

Sanofi Gains FDA Annual Approval for Fluzone and Fluzone High-Dose for 2026–27 Season

FDA grants Sanofi concurrent annual approval for Fluzone and Fluzone High-Dose, confirming 2026–27 seasonal authorization under STN BL 103914.

Pharma Now Editorial TeamJul 03, 2026Read more
Sanofi Gains FDA Annual Approval for Fluzone and Fluzone High-Dose for 2026–27 Season
NewsNew

ID Biomedical Gains FDA Approval for FluLaval Quadrivalent Ahead of 2026–2027 Influenza Season

FDA approves FluLaval Quadrivalent for 2026–2027 season; lot release and GMP compliance timelines now active for ID Biomedical.

Pharma Now Editorial TeamJul 03, 2026Read more
ID Biomedical Gains FDA Approval for FluLaval Quadrivalent Ahead of 2026–2027 Influenza Season
News

Seqirus Gains FDA Approval for Flucelvax for 2026–2027 Influenza Season

FDA approves Seqirus Flucelvax for 2026–2027 season on July 1, continuing annual cell-based influenza vaccine approval cycle.

Pharma Now Editorial TeamJul 03, 2026Read more
Seqirus Gains FDA Approval for Flucelvax for 2026–2027 Influenza Season
News

FDA Investigates Sevoflurane Safety After Neurologic Deaths Linked to Mitochondrial Variant in Venezuelan-Ancestry Patients

FDA is investigating sevoflurane and volatile anesthetics after neurologic deaths linked to a rare mitochondrial variant in Venezuelan-ancestry patients.

Pharma Now Editorial TeamJul 03, 2026Read more
FDA Investigates Sevoflurane Safety After Neurologic Deaths Linked to Mitochondrial Variant in Venezuelan-Ancestry Patients
News

FDA Updates Authorized Generics Listing, Flagging Data Gaps NDA Sponsors Must Verify

FDA's July 2026 authorized generics update flags data gaps NDA sponsors must independently verify before relying on market-entry timelines.

Pharma Now Editorial TeamJul 03, 2026Read more
FDA Updates Authorized Generics Listing, Flagging Data Gaps NDA Sponsors Must Verify
News

Glenmark Advances Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark moves a HER2-targeted ADC into Phase 3 for platinum-resistant ovarian cancer, raising GMP and process validation considerations for ADC manufacturing at scale.

Vaibhavi M.Jul 02, 2026Read more
Glenmark Advances Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
News

Syngene Appoints Siddharth Mittal as MD and CEO Following Leadership Transition

Syngene names Siddharth Mittal MD and CEO; his 13-year CFO tenure at Biocon shapes expectations for CDMO capacity and partnership strategy.

Vaibhavi M.Jul 02, 2026Read more
Syngene Appoints Siddharth Mittal as MD and CEO Following Leadership Transition
News

NKGen Biotech Presents Troculeucel NK Cell Therapy at BIOCHINA 2026 Forum in Seoul

NKGen Biotech's CEO will present troculeucel's Phase 2 data and China free-trade zone regulatory pathways at BIOCHINA 2026 in Seoul on July 10.

Pharma Now Editorial TeamJul 02, 2026Read more
NKGen Biotech Presents Troculeucel NK Cell Therapy at BIOCHINA 2026 Forum in Seoul
News

GlaxoSmithKline Gains FDA CBER Approval for Fluarix Seasonal Strain Update in March 2026

FDA CBER issued a March 2026 approval letter for GlaxoSmithKline's Fluarix, shifting the seasonal strain update timeline earlier than prior years.

Vaibhavi M.Jul 02, 2026Read more
GlaxoSmithKline Gains FDA CBER Approval for Fluarix Seasonal Strain Update in March 2026
News

EMA Launches Women's Health Initiative Targeting Clinical Trial Design and Labelling Requirements

EMA formalises a women's health initiative across four workstreams, with clinical trial design and labelling obligations set for review ahead of a September workshop.

Vaibhavi M.Jul 02, 2026Read more
EMA Launches Women's Health Initiative Targeting Clinical Trial Design and Labelling Requirements
News

Corline Biomedical Achieves 60-Month Safety Confirmation for Renaparin in Kidney Transplantation

Corline Biomedical's 60-month STARS-nob data confirm Renaparin® safety and signal eGFR benefit, supporting progression to the 80-patient RENAPAIR 02 trial.

Vaibhavi M.Jul 02, 2026Read more
Corline Biomedical Achieves 60-Month Safety Confirmation for Renaparin in Kidney Transplantation

Trending now

Most-read this hour

1

WHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC Outbreak

News · Jul 03, 2026
2

WHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and Remdesivir

News · Jul 03, 2026
3

Aarti Pharmalabs Inaugurates Tarapur Block, Lifting Xanthine Derivatives Capacity to 9,600 TPA

News · Jul 03, 2026
4

Rockwell Automation and Cisco Sign Manufacturing Partnership to Advance AI-Driven Operations in India

AI in pharma · Jul 03, 2026
5

Roche Establishes Second India Digital Tech Hub in Hyderabad for Global Operations

News · Jul 03, 2026
The signal
The week in pharma, distilled

One considered email — the stories, moves and numbers that matter, every Friday.

Editor’s picks

Worth your time this week

Back to top ↑
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer to Lead ANV200 IND Strategy
News

Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer to Lead ANV200 IND Strategy

Vaibhavi M.Jul 02, 2026
Roche Achieves Phase III Superiority for Divarasib Against Approved KRAS G12C Inhibitors in NSCLC
News

Roche Achieves Phase III Superiority for Divarasib Against Approved KRAS G12C Inhibitors in NSCLC

Pharma Now Editorial TeamJul 02, 2026
Novartis Gains European Commission Approval for Itvisma in Broad SMA Population
News

Novartis Gains European Commission Approval for Itvisma in Broad SMA Population

Pharma Now Editorial TeamJul 02, 2026
Morepen Begins Commercial Supplies Under Rs. 825 Crore CDMO Contract
News

Morepen Begins Commercial Supplies Under Rs. 825 Crore CDMO Contract

Pharma Now Editorial TeamJul 02, 2026